Cargando…

Hypofractionated ablative radiotherapy for locally advanced pancreatic cancer

The role of radiation in locally advanced unresectable pancreatic cancer (LAPC) is controversial. Randomized trials evaluating standard doses of chemoradiation have not shown a significant benefit from the use of consolidative radiation. Results from non-randomized studies of 3–5-fraction stereotact...

Descripción completa

Detalles Bibliográficos
Autor principal:	Crane, Christopher H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Supplement – ICRR highlights
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4990109/ https://www.ncbi.nlm.nih.gov/pubmed/27029741 http://dx.doi.org/10.1093/jrr/rrw016

Ejemplares similares

Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules?
por: Shibamoto, Yuta, et al.
Publicado: (2016)

The complexity of microRNAs in human cancer
por: Kwan, Jennifer Y. Y., et al.
Publicado: (2016)

IMRT for head and neck cancer: reducing xerostomia and dysphagia
por: Wang, XiaoShen, et al.
Publicado: (2016)

Epidemiological research on radiation-induced cancer in atomic bomb survivors
por: Ozasa, Kotaro
Publicado: (2016)

Hypoxia-inducible factor 1–mediated characteristic features of cancer cells for tumor radioresistance
por: Harada, Hiroshi
Publicado: (2016)

Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach
por: Ricardi, Umberto, et al.
Publicado: (2016)

In vivo sensitivity of the embryonic and adult neural stem cell compartments to low-dose radiation
por: Barazzuol, Lara, et al.
Publicado: (2016)

Life science experiments performed in space in the ISS/Kibo facility and future research plans
por: Ohnishi, Takeo
Publicado: (2016)

An analysis of the structure of the compound biological effectiveness factor
por: Ono, Koji
Publicado: (2016)

Opposing roles of RNF8/RNF168 and deubiquitinating enzymes in ubiquitination-dependent DNA double-strand break response signaling and DNA-repair pathway choice
por: Nakada, Shinichiro
Publicado: (2016)

NBS1 and multiple regulations of DNA damage response
por: Komatsu, Kenshi
Publicado: (2016)

Unsolved mystery: the role of BRCA1 in DNA end-joining
por: Saha, Janapriya, et al.
Publicado: (2016)

The role of the Mre11–Rad50–Nbs1 complex in double-strand break repair—facts and myths
por: Takeda, Shunichi, et al.
Publicado: (2016)

Internal thyroid doses to Fukushima residents—estimation and issues remaining
por: Kim, Eunjoo, et al.
Publicado: (2016)

The impact of hypoxia and its modification of the outcome of radiotherapy
por: Horsman, Michael R., et al.
Publicado: (2016)

Agricultural implications of the Fukushima nuclear accident
por: Nakanishi, Tomoko M.
Publicado: (2016)

Hypofractionated Radiotherapy as Local Hemostatic Agent in Advanced Cancer
por: Rasool, Malik Tariq, et al.
Publicado: (2011)

Comparison of the dose escalation potential for two hypofractionated radiotherapy regimens for locally advanced pancreatic cancer
por: Bertholet, Jenny, et al.
Publicado: (2019)

Hypofractionated Radiotherapy for Palliation in Locally Advanced Head and Neck Cancer
por: Spartacus, RK, et al.
Publicado: (2017)

Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results
por: Reyngold, Marsha, et al.
Publicado: (2019)

Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma
por: Iwai, Takahiro, et al.
Publicado: (2020)

Hypofractionated vs. standard radiotherapy for locally advanced limited-stage small cell lung cancer
por: Saeed, Nadia A., et al.
Publicado: (2022)

Radiotherapy and the tumor microenvironment: The “macro” picture
por: Walton, Emma Louise
Publicado: (2017)

External beam radiotherapy for localized prostate cancer
por: Yilmaz, Hasan, et al.
Publicado: (2015)

Clinical impact of Hypofractionated carbon ion radiotherapy on locally advanced hepatocellular carcinoma
por: Shiba, Shintaro, et al.
Publicado: (2020)

Hypofractionated Palliative Radiotherapy in Locally Advanced Inoperable Head and Neck Cancer: CMC Vellore Experience
por: Das, Saikat, et al.
Publicado: (2013)

Hypofractionated radiotherapy in postmastectomy locally advanced breast cancer: an interim report on acute toxicities and dosimetry
por: Jamora, Kurl, et al.
Publicado: (2022)

Hypofractionated radiotherapy for prostate cancer
por: Hegemann, Nina-Sophie, et al.
Publicado: (2014)

Rewiring local immune milieu by boosting dendritic cell for pancreatic cancer treatment
por: Zhang, Yifan, et al.
Publicado: (2020)

Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer
por: Rossi, Gabriella, et al.
Publicado: (2021)

Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021)

Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?
por: Simoni, Nicola, et al.
Publicado: (2022)

Review of Hypofractionated Radiotherapy for Prostate Cancer
por: Spyropoulou, Despina, et al.
Publicado: (2012)

The Role of Hypofractionated Radiotherapy in Prostate Cancer
por: Benjamin, Linus C., et al.
Publicado: (2017)

Hypofractionated Radiotherapy in African Cancer Centers
por: Swanson, William, et al.
Publicado: (2021)

Advances in radiotherapy for brain metastases
por: Gondi, Vinai, et al.
Publicado: (2021)

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma
por: Jacinto, Alexandre Arthur, et al.
Publicado: (2018)

Salvage brachytherapy for locally recurrent prostate cancer after external beam radiotherapy
por: Yamada, Yasuhiro, et al.
Publicado: (2015)

Long-Term Outcomes of Dose-Escalated Hypofractionated Radiotherapy in Localized Prostate Cancer
por: Lazo, Antonio, et al.
Publicado: (2022)

Margetuximab: An active alternative for later‐line therapy in patients with HER2‐positive advanced breast cancer
por: Zhou, Yunxiang, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_832bmknrrmghtjdb6akifjq3o8